The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, outlines a Phase II study (NCT03404193) of venetoclax in combination with 10-day decitabine in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
